|Description||CK-119, a dihydropyridazino-pyridazine compound, is a potent IL-1 blocker to inhibit cell growth of fibroblast-like corneal and conjunctival cells mainly through the inhibition of DNA and RNA syntheses but not protein synthesis.|
|Synonyms||diethyl 6-[(4-chlorophenyl)methyl]-1,4-dimethyl-5-oxopyridazino[4,5-c]pyridazine-3,4-dicarboxylate; CK-119; CK119; CK 119; UNII-AL53N923EI; GC-6119; GC 6119; GC6119|
|Boiling Point||277.4ºC at 760 mmHg|
APY0201, an effective IL-12/23 inhibitor, has been found to have potential useful in treatment of inflammation. IC50: 5.2 nM .
Veledimex racemate is the racemate of veledimex. Veledimex is an orally active small molecule diacylhydrazine and controls the expression of the target gene.
Ladarixin is Interleukin 8A and Interleukin 8B receptor antagonist. IL-8A and IL-8B inhibition blocks and reverses type 1 diabetes in mice. In Dec 2015, Phase-I...
CP 424174 has been found to be an inhibitor of stimulus-coupled IL-1β post-translational processing.
Secukinumab is a recombinant human IgG1κ monoclonal antibody that specifically binds to and inhibits interleukin (IL)-17A. Secukinumab was developed by Novartis...
BMS-279700, belonging to a family of novel anilino 5-azaimidazoquinoxaline analogues, is an orally active lead candidate that blocks the production of proinflam...
Reslizumab is a humanized monoclonal antibody resistant to interleukin-5 (IL-5). It is approved for additional maintenance treatment of patients with severe ast...
The mesylate salt form of Apilimod. Apilimod is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with ...